CORT - Hazel Hunt Sees Potential Growth And Acquires $105K In Corcept Therapeutics Stock Options | Benzinga
In a new SEC filing on February 14, it was unveiled that Hunt, Chief Scientific Officer at Corcept Therapeutics (NASDAQ:CORT), acquired stock options for 200,000 shares.
What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Hunt, Chief Scientific Officer at Corcept Therapeutics, acquired 200,000 stock options for CORT with an exercise price of $23.01 per share.
The Wednesday morning update indicates Corcept Therapeutics shares down by 0.0%, currently priced at $23.05. At this value, Hunt's 200,000 shares are worth $105,999.
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Milestones: Corcept Therapeutics's Journey
Revenue Growth: Over the 3 months period, Corcept Therapeutics showcased positive performance, achieving a revenue growth rate of 21.5% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Exploring Profitability:
-
Gross Margin: With a ...